M. Phillip DeYoung
As a research fellow in Leif Ellisen's lab, was first author on the 2008 study showing that hypoxia switches off mTORC1 through REDD1 releasing TSC2 from 14-3-3 proteins
Scientist in oncology research and development at GSK · research fellow with Leif Ellisen, Massachusetts General Hospital Cancer Center & Harvard Medical School · PhD with Ram Narayanan, Florida Atlantic University
Lab lineagetrained under Leif W. Ellisen →
Phillip DeYoung was first author of the Atlas study showing how low oxygen turns mTORC1 off: REDD1 frees TSC2 from inhibitory 14-3-3 proteins so that TSC2 can act, and cells lacking REDD1 fail to switch mTORC1 off in hypoxia and grow into larger tumours in mice (DEY2008).
DeYoung earned his PhD at Florida Atlantic University with Ram Narayanan, working on bioinformatic discovery of cancer genes, then joined Leif Ellisen's lab at the MGH Cancer Center as a research fellow. He moved into drug discovery at GSK, where he has worked in oncology research and development.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2008 | M | Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling DEY2008 First author: showed that hypoxia inhibits mTORC1 through REDD1-driven release of TSC2 from 14-3-3 proteins. |
Co-authors in the Atlas
People with a profile here who share at least one study with M. Phillip DeYoung.
- Leif W. Ellisen Physician-scientist whose lab studies REDD1, a stress-induced inhibitor of mTORC1, and showed how hypoxia uses REDD1 to release TSC2 from 14-3-3 proteins
Every researcher with a profile →
Thank you. Your answer was counted anonymously.
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.